Edwards Lifesciences Corporation $EW Stock Position Trimmed by Nordea Investment Management AB

Nordea Investment Management AB trimmed its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,246,964 shares of the medical research company’s stock after selling 110,464 shares during the period. Nordea Investment Management AB’s holdings in Edwards Lifesciences were worth $328,545,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Edwards Lifesciences by 1.2% in the 2nd quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after purchasing an additional 798,801 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Edwards Lifesciences by 0.4% in the 2nd quarter. Geode Capital Management LLC now owns 12,722,416 shares of the medical research company’s stock valued at $990,074,000 after buying an additional 45,555 shares in the last quarter. Jennison Associates LLC boosted its stake in shares of Edwards Lifesciences by 15.7% during the 2nd quarter. Jennison Associates LLC now owns 11,670,991 shares of the medical research company’s stock worth $912,788,000 after acquiring an additional 1,584,958 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its holdings in Edwards Lifesciences by 111.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock valued at $714,006,000 after acquiring an additional 4,805,819 shares during the period. Finally, Ninety One UK Ltd increased its position in Edwards Lifesciences by 14.0% during the third quarter. Ninety One UK Ltd now owns 7,908,572 shares of the medical research company’s stock worth $615,050,000 after acquiring an additional 969,030 shares during the period. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of a number of analyst reports. Royal Bank Of Canada raised their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, December 5th. JPMorgan Chase & Co. upgraded Edwards Lifesciences from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $90.00 to $100.00 in a research report on Thursday, December 18th. BTIG Research reaffirmed a “buy” rating and set a $103.00 price target (up previously from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Finally, TD Cowen upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their target price for the company from $90.00 to $97.00 in a research note on Friday. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and a consensus price target of $94.87.

Edwards Lifesciences Trading Down 2.4%

EW opened at $83.07 on Tuesday. The stock has a market cap of $48.20 billion, a PE ratio of 35.80, a price-to-earnings-growth ratio of 3.46 and a beta of 0.95. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89. The company has a fifty day moving average of $85.06 and a 200-day moving average of $80.42. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the previous year, the company posted $0.67 EPS. The company’s revenue for the quarter was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction on Monday, November 10th. The stock was sold at an average price of $83.08, for a total value of $1,080,040.00. Following the completion of the sale, the chief financial officer owned 39,898 shares in the company, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,386 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $83.76, for a total value of $953,691.36. Following the completion of the sale, the vice president owned 38,970 shares in the company, valued at $3,264,127.20. This represents a 22.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 57,824 shares of company stock valued at $4,863,323. Insiders own 0.34% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.